nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—ADRA1B—vas deferens—testicular cancer	0.0873	0.62	CbGeAlD
Paliperidone—CYP3A5—Ifosfamide—testicular cancer	0.061	0.343	CbGbCtD
Paliperidone—CYP3A5—Etoposide—testicular cancer	0.0291	0.164	CbGbCtD
Paliperidone—CYP3A4—Ifosfamide—testicular cancer	0.0238	0.134	CbGbCtD
Paliperidone—CYP2D6—Vinblastine—testicular cancer	0.0198	0.112	CbGbCtD
Paliperidone—HTR2A—vein—testicular cancer	0.0135	0.0957	CbGeAlD
Paliperidone—CYP3A4—Vinblastine—testicular cancer	0.0126	0.071	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—testicular cancer	0.0122	0.0686	CbGbCtD
Paliperidone—CYP3A4—Etoposide—testicular cancer	0.0114	0.064	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—testicular cancer	0.00775	0.0436	CbGbCtD
Paliperidone—DRD4—testis—testicular cancer	0.00636	0.0452	CbGeAlD
Paliperidone—ADRA2C—seminal vesicle—testicular cancer	0.00353	0.0251	CbGeAlD
Paliperidone—ADRA2A—seminal vesicle—testicular cancer	0.00282	0.02	CbGeAlD
Paliperidone—HTR2A—embryo—testicular cancer	0.00255	0.0181	CbGeAlD
Paliperidone—ADRA2C—female gonad—testicular cancer	0.00207	0.0147	CbGeAlD
Paliperidone—ADRA2A—gonad—testicular cancer	0.00204	0.0145	CbGeAlD
Paliperidone—DRD2—testis—testicular cancer	0.00189	0.0134	CbGeAlD
Paliperidone—ADRA2C—testis—testicular cancer	0.00184	0.0131	CbGeAlD
Paliperidone—CYP3A5—female gonad—testicular cancer	0.00174	0.0123	CbGeAlD
Paliperidone—HTR2A—gonad—testicular cancer	0.00173	0.0123	CbGeAlD
Paliperidone—HRH1—female gonad—testicular cancer	0.00168	0.012	CbGeAlD
Paliperidone—ADRA2A—female gonad—testicular cancer	0.00165	0.0118	CbGeAlD
Paliperidone—HRH1—testis—testicular cancer	0.00149	0.0106	CbGeAlD
Paliperidone—ADRA2A—testis—testicular cancer	0.00147	0.0104	CbGeAlD
Paliperidone—ADRA2C—lymph node—testicular cancer	0.00133	0.00947	CbGeAlD
Paliperidone—CYP2D6—female gonad—testicular cancer	0.00128	0.0091	CbGeAlD
Paliperidone—HTR2A—testis—testicular cancer	0.00125	0.00886	CbGeAlD
Paliperidone—CYP2D6—testis—testicular cancer	0.00114	0.00807	CbGeAlD
Paliperidone—HRH1—lymph node—testicular cancer	0.00108	0.00769	CbGeAlD
Paliperidone—ADRA2A—lymph node—testicular cancer	0.00106	0.00755	CbGeAlD
Paliperidone—Dermatitis—Ifosfamide—testicular cancer	0.000388	0.000569	CcSEcCtD
Paliperidone—Urticaria—Etoposide—testicular cancer	0.000386	0.000566	CcSEcCtD
Paliperidone—Jaundice—Doxorubicin—testicular cancer	0.000385	0.000565	CcSEcCtD
Paliperidone—Rhinitis—Epirubicin—testicular cancer	0.000384	0.000564	CcSEcCtD
Paliperidone—Body temperature increased—Etoposide—testicular cancer	0.000384	0.000564	CcSEcCtD
Paliperidone—Abdominal pain—Etoposide—testicular cancer	0.000384	0.000564	CcSEcCtD
Paliperidone—Conjunctivitis—Doxorubicin—testicular cancer	0.000384	0.000564	CcSEcCtD
Paliperidone—Urinary tract infection—Doxorubicin—testicular cancer	0.000384	0.000564	CcSEcCtD
Paliperidone—Eye disorder—Methotrexate—testicular cancer	0.000383	0.000562	CcSEcCtD
Paliperidone—Tinnitus—Methotrexate—testicular cancer	0.000382	0.00056	CcSEcCtD
Paliperidone—Hypoaesthesia—Epirubicin—testicular cancer	0.000381	0.00056	CcSEcCtD
Paliperidone—Asthenia—Cisplatin—testicular cancer	0.000381	0.000558	CcSEcCtD
Paliperidone—Cardiac disorder—Methotrexate—testicular cancer	0.00038	0.000558	CcSEcCtD
Paliperidone—Urinary tract disorder—Epirubicin—testicular cancer	0.000379	0.000555	CcSEcCtD
Paliperidone—Oedema peripheral—Epirubicin—testicular cancer	0.000378	0.000554	CcSEcCtD
Paliperidone—Connective tissue disorder—Epirubicin—testicular cancer	0.000377	0.000553	CcSEcCtD
Paliperidone—Urethral disorder—Epirubicin—testicular cancer	0.000376	0.000551	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—testicular cancer	0.000374	0.000548	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—testicular cancer	0.000373	0.000547	CcSEcCtD
Paliperidone—Angiopathy—Methotrexate—testicular cancer	0.000372	0.000545	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—testicular cancer	0.000371	0.000544	CcSEcCtD
Paliperidone—Immune system disorder—Methotrexate—testicular cancer	0.00037	0.000543	CcSEcCtD
Paliperidone—Mediastinal disorder—Methotrexate—testicular cancer	0.000369	0.000542	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—testicular cancer	0.000369	0.000541	CcSEcCtD
Paliperidone—Chills—Methotrexate—testicular cancer	0.000368	0.000539	CcSEcCtD
Paliperidone—Nausea—Ifosfamide—testicular cancer	0.000365	0.000536	CcSEcCtD
Paliperidone—Diarrhoea—Cisplatin—testicular cancer	0.000363	0.000532	CcSEcCtD
Paliperidone—Alopecia—Methotrexate—testicular cancer	0.000362	0.000531	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—testicular cancer	0.000361	0.00053	CcSEcCtD
Paliperidone—Mental disorder—Methotrexate—testicular cancer	0.000359	0.000527	CcSEcCtD
Paliperidone—Eye disorder—Epirubicin—testicular cancer	0.000358	0.000526	CcSEcCtD
Paliperidone—Hypersensitivity—Etoposide—testicular cancer	0.000358	0.000525	CcSEcCtD
Paliperidone—Tinnitus—Epirubicin—testicular cancer	0.000357	0.000524	CcSEcCtD
Paliperidone—Malnutrition—Methotrexate—testicular cancer	0.000357	0.000523	CcSEcCtD
Paliperidone—Erythema—Methotrexate—testicular cancer	0.000357	0.000523	CcSEcCtD
Paliperidone—Cardiac disorder—Epirubicin—testicular cancer	0.000356	0.000522	CcSEcCtD
Paliperidone—Flushing—Epirubicin—testicular cancer	0.000356	0.000522	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—testicular cancer	0.000356	0.000522	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—testicular cancer	0.000353	0.000518	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—testicular cancer	0.00035	0.000514	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—testicular cancer	0.000349	0.000513	CcSEcCtD
Paliperidone—Dysgeusia—Methotrexate—testicular cancer	0.000349	0.000512	CcSEcCtD
Paliperidone—Asthenia—Etoposide—testicular cancer	0.000349	0.000511	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—testicular cancer	0.000349	0.000511	CcSEcCtD
Paliperidone—Angiopathy—Epirubicin—testicular cancer	0.000348	0.00051	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—testicular cancer	0.000348	0.00051	CcSEcCtD
Paliperidone—Immune system disorder—Epirubicin—testicular cancer	0.000346	0.000508	CcSEcCtD
Paliperidone—Mediastinal disorder—Epirubicin—testicular cancer	0.000346	0.000507	CcSEcCtD
Paliperidone—Back pain—Methotrexate—testicular cancer	0.000345	0.000506	CcSEcCtD
Paliperidone—Chills—Epirubicin—testicular cancer	0.000344	0.000505	CcSEcCtD
Paliperidone—Pruritus—Etoposide—testicular cancer	0.000344	0.000504	CcSEcCtD
Paliperidone—Alopecia—Epirubicin—testicular cancer	0.000339	0.000497	CcSEcCtD
Paliperidone—Vomiting—Cisplatin—testicular cancer	0.000337	0.000495	CcSEcCtD
Paliperidone—Vision blurred—Methotrexate—testicular cancer	0.000336	0.000493	CcSEcCtD
Paliperidone—Mental disorder—Epirubicin—testicular cancer	0.000336	0.000493	CcSEcCtD
Paliperidone—Rash—Cisplatin—testicular cancer	0.000334	0.000491	CcSEcCtD
Paliperidone—Dermatitis—Cisplatin—testicular cancer	0.000334	0.00049	CcSEcCtD
Paliperidone—Erythema—Epirubicin—testicular cancer	0.000334	0.00049	CcSEcCtD
Paliperidone—Malnutrition—Epirubicin—testicular cancer	0.000334	0.00049	CcSEcCtD
Paliperidone—Diarrhoea—Etoposide—testicular cancer	0.000332	0.000488	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—testicular cancer	0.000332	0.000486	CcSEcCtD
Paliperidone—Ill-defined disorder—Methotrexate—testicular cancer	0.000331	0.000485	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—testicular cancer	0.000331	0.000485	CcSEcCtD
Paliperidone—Anaemia—Methotrexate—testicular cancer	0.00033	0.000484	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—testicular cancer	0.000329	0.000483	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—testicular cancer	0.000329	0.000483	CcSEcCtD
Paliperidone—Flatulence—Epirubicin—testicular cancer	0.000329	0.000482	CcSEcCtD
Paliperidone—Tension—Epirubicin—testicular cancer	0.000328	0.00048	CcSEcCtD
Paliperidone—Dysgeusia—Epirubicin—testicular cancer	0.000327	0.000479	CcSEcCtD
Paliperidone—Nervousness—Epirubicin—testicular cancer	0.000324	0.000476	CcSEcCtD
Paliperidone—Back pain—Epirubicin—testicular cancer	0.000323	0.000474	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—testicular cancer	0.000322	0.000472	CcSEcCtD
Paliperidone—Malaise—Methotrexate—testicular cancer	0.000322	0.000472	CcSEcCtD
Paliperidone—Dizziness—Etoposide—testicular cancer	0.000321	0.000471	CcSEcCtD
Paliperidone—Muscle spasms—Epirubicin—testicular cancer	0.000321	0.000471	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—testicular cancer	0.00032	0.00047	CcSEcCtD
Paliperidone—Vertigo—Methotrexate—testicular cancer	0.00032	0.00047	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—testicular cancer	0.00032	0.000469	CcSEcCtD
Paliperidone—Leukopenia—Methotrexate—testicular cancer	0.000319	0.000468	CcSEcCtD
Paliperidone—Chills—Doxorubicin—testicular cancer	0.000318	0.000467	CcSEcCtD
Paliperidone—Nausea—Cisplatin—testicular cancer	0.000315	0.000462	CcSEcCtD
Paliperidone—Vision blurred—Epirubicin—testicular cancer	0.000315	0.000461	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—testicular cancer	0.000313	0.00046	CcSEcCtD
Paliperidone—Cough—Methotrexate—testicular cancer	0.000311	0.000457	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—testicular cancer	0.000311	0.000456	CcSEcCtD
Paliperidone—Ill-defined disorder—Epirubicin—testicular cancer	0.00031	0.000454	CcSEcCtD
Paliperidone—Convulsion—Methotrexate—testicular cancer	0.000309	0.000453	CcSEcCtD
Paliperidone—Vomiting—Etoposide—testicular cancer	0.000309	0.000453	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—testicular cancer	0.000309	0.000453	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—testicular cancer	0.000309	0.000453	CcSEcCtD
Paliperidone—Anaemia—Epirubicin—testicular cancer	0.000308	0.000453	CcSEcCtD
Paliperidone—Agitation—Epirubicin—testicular cancer	0.000307	0.00045	CcSEcCtD
Paliperidone—Rash—Etoposide—testicular cancer	0.000306	0.000449	CcSEcCtD
Paliperidone—Dermatitis—Etoposide—testicular cancer	0.000306	0.000449	CcSEcCtD
Paliperidone—Headache—Etoposide—testicular cancer	0.000304	0.000447	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—testicular cancer	0.000304	0.000446	CcSEcCtD
Paliperidone—Chest pain—Methotrexate—testicular cancer	0.000304	0.000445	CcSEcCtD
Paliperidone—Arthralgia—Methotrexate—testicular cancer	0.000304	0.000445	CcSEcCtD
Paliperidone—Myalgia—Methotrexate—testicular cancer	0.000304	0.000445	CcSEcCtD
Paliperidone—Tension—Doxorubicin—testicular cancer	0.000303	0.000445	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—testicular cancer	0.000302	0.000444	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—testicular cancer	0.000302	0.000442	CcSEcCtD
Paliperidone—Malaise—Epirubicin—testicular cancer	0.000301	0.000442	CcSEcCtD
Paliperidone—Discomfort—Methotrexate—testicular cancer	0.0003	0.00044	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—testicular cancer	0.0003	0.00044	CcSEcCtD
Paliperidone—Vertigo—Epirubicin—testicular cancer	0.0003	0.00044	CcSEcCtD
Paliperidone—Syncope—Epirubicin—testicular cancer	0.000299	0.000439	CcSEcCtD
Paliperidone—Leukopenia—Epirubicin—testicular cancer	0.000299	0.000438	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—testicular cancer	0.000299	0.000438	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—testicular cancer	0.000297	0.000436	CcSEcCtD
Paliperidone—Palpitations—Epirubicin—testicular cancer	0.000295	0.000433	CcSEcCtD
Paliperidone—Confusional state—Methotrexate—testicular cancer	0.000293	0.000431	CcSEcCtD
Paliperidone—Loss of consciousness—Epirubicin—testicular cancer	0.000293	0.00043	CcSEcCtD
Paliperidone—Cough—Epirubicin—testicular cancer	0.000291	0.000427	CcSEcCtD
Paliperidone—Anaphylactic shock—Methotrexate—testicular cancer	0.000291	0.000427	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—testicular cancer	0.000291	0.000427	CcSEcCtD
Paliperidone—Convulsion—Epirubicin—testicular cancer	0.000289	0.000424	CcSEcCtD
Paliperidone—Infection—Methotrexate—testicular cancer	0.000289	0.000424	CcSEcCtD
Paliperidone—Nausea—Etoposide—testicular cancer	0.000289	0.000423	CcSEcCtD
Paliperidone—Hypertension—Epirubicin—testicular cancer	0.000288	0.000423	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—testicular cancer	0.000287	0.00042	CcSEcCtD
Paliperidone—Nervous system disorder—Methotrexate—testicular cancer	0.000285	0.000419	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—testicular cancer	0.000285	0.000419	CcSEcCtD
Paliperidone—Thrombocytopenia—Methotrexate—testicular cancer	0.000285	0.000418	CcSEcCtD
Paliperidone—Arthralgia—Epirubicin—testicular cancer	0.000284	0.000417	CcSEcCtD
Paliperidone—Chest pain—Epirubicin—testicular cancer	0.000284	0.000417	CcSEcCtD
Paliperidone—Myalgia—Epirubicin—testicular cancer	0.000284	0.000417	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—testicular cancer	0.000284	0.000416	CcSEcCtD
Paliperidone—Anxiety—Epirubicin—testicular cancer	0.000283	0.000415	CcSEcCtD
Paliperidone—Skin disorder—Methotrexate—testicular cancer	0.000283	0.000415	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—testicular cancer	0.000282	0.000414	CcSEcCtD
Paliperidone—Discomfort—Epirubicin—testicular cancer	0.000281	0.000412	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—testicular cancer	0.000278	0.000409	CcSEcCtD
Paliperidone—Dry mouth—Epirubicin—testicular cancer	0.000278	0.000408	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—testicular cancer	0.000277	0.000407	CcSEcCtD
Paliperidone—Anorexia—Methotrexate—testicular cancer	0.000277	0.000407	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—testicular cancer	0.000277	0.000406	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—testicular cancer	0.000276	0.000406	CcSEcCtD
Paliperidone—Confusional state—Epirubicin—testicular cancer	0.000275	0.000403	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—testicular cancer	0.000273	0.0004	CcSEcCtD
Paliperidone—Oedema—Epirubicin—testicular cancer	0.000272	0.0004	CcSEcCtD
Paliperidone—Anaphylactic shock—Epirubicin—testicular cancer	0.000272	0.0004	CcSEcCtD
Paliperidone—Hypotension—Methotrexate—testicular cancer	0.000272	0.000399	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—testicular cancer	0.000271	0.000398	CcSEcCtD
Paliperidone—Infection—Epirubicin—testicular cancer	0.000271	0.000397	CcSEcCtD
Paliperidone—Cough—Doxorubicin—testicular cancer	0.000269	0.000395	CcSEcCtD
Paliperidone—Shock—Epirubicin—testicular cancer	0.000268	0.000393	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—testicular cancer	0.000268	0.000393	CcSEcCtD
Paliperidone—Nervous system disorder—Epirubicin—testicular cancer	0.000267	0.000392	CcSEcCtD
Paliperidone—Thrombocytopenia—Epirubicin—testicular cancer	0.000267	0.000391	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—testicular cancer	0.000267	0.000391	CcSEcCtD
Paliperidone—Tachycardia—Epirubicin—testicular cancer	0.000266	0.00039	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.000265	0.000389	CcSEcCtD
Paliperidone—Skin disorder—Epirubicin—testicular cancer	0.000265	0.000388	CcSEcCtD
Paliperidone—Insomnia—Methotrexate—testicular cancer	0.000263	0.000386	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—testicular cancer	0.000263	0.000386	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—testicular cancer	0.000263	0.000386	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—testicular cancer	0.000263	0.000386	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—testicular cancer	0.000262	0.000384	CcSEcCtD
Paliperidone—Paraesthesia—Methotrexate—testicular cancer	0.000261	0.000383	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—testicular cancer	0.000261	0.000383	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—testicular cancer	0.00026	0.000381	CcSEcCtD
Paliperidone—Anorexia—Epirubicin—testicular cancer	0.00026	0.000381	CcSEcCtD
Paliperidone—Dyspnoea—Methotrexate—testicular cancer	0.000259	0.000381	CcSEcCtD
Paliperidone—Somnolence—Methotrexate—testicular cancer	0.000259	0.00038	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—testicular cancer	0.000257	0.000377	CcSEcCtD
Paliperidone—Dyspepsia—Methotrexate—testicular cancer	0.000256	0.000376	CcSEcCtD
Paliperidone—Hypotension—Epirubicin—testicular cancer	0.000255	0.000373	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—testicular cancer	0.000254	0.000373	CcSEcCtD
Paliperidone—Decreased appetite—Methotrexate—testicular cancer	0.000253	0.000371	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—testicular cancer	0.000252	0.00037	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—testicular cancer	0.000252	0.00037	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Methotrexate—testicular cancer	0.000251	0.000369	CcSEcCtD
Paliperidone—Fatigue—Methotrexate—testicular cancer	0.000251	0.000368	CcSEcCtD
Paliperidone—Infection—Doxorubicin—testicular cancer	0.00025	0.000367	CcSEcCtD
Paliperidone—Pain—Methotrexate—testicular cancer	0.000249	0.000365	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.000248	0.000364	CcSEcCtD
Paliperidone—Shock—Doxorubicin—testicular cancer	0.000248	0.000364	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—testicular cancer	0.000247	0.000363	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—testicular cancer	0.000247	0.000362	CcSEcCtD
Paliperidone—Insomnia—Epirubicin—testicular cancer	0.000246	0.000361	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—testicular cancer	0.000246	0.000361	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—testicular cancer	0.000245	0.000359	CcSEcCtD
Paliperidone—Paraesthesia—Epirubicin—testicular cancer	0.000245	0.000359	CcSEcCtD
Paliperidone—Dyspnoea—Epirubicin—testicular cancer	0.000243	0.000356	CcSEcCtD
Paliperidone—Somnolence—Epirubicin—testicular cancer	0.000242	0.000355	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—testicular cancer	0.00024	0.000352	CcSEcCtD
Paliperidone—Feeling abnormal—Methotrexate—testicular cancer	0.00024	0.000352	CcSEcCtD
Paliperidone—Dyspepsia—Epirubicin—testicular cancer	0.00024	0.000352	CcSEcCtD
Paliperidone—Gastrointestinal pain—Methotrexate—testicular cancer	0.000238	0.000349	CcSEcCtD
Paliperidone—Decreased appetite—Epirubicin—testicular cancer	0.000237	0.000347	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—testicular cancer	0.000235	0.000345	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Epirubicin—testicular cancer	0.000235	0.000345	CcSEcCtD
Paliperidone—Fatigue—Epirubicin—testicular cancer	0.000235	0.000345	CcSEcCtD
Paliperidone—Pain—Epirubicin—testicular cancer	0.000233	0.000342	CcSEcCtD
Paliperidone—Constipation—Epirubicin—testicular cancer	0.000233	0.000342	CcSEcCtD
Paliperidone—Urticaria—Methotrexate—testicular cancer	0.000231	0.000339	CcSEcCtD
Paliperidone—Abdominal pain—Methotrexate—testicular cancer	0.00023	0.000338	CcSEcCtD
Paliperidone—Body temperature increased—Methotrexate—testicular cancer	0.00023	0.000338	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.00023	0.000337	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—testicular cancer	0.000228	0.000334	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—testicular cancer	0.000226	0.000332	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—testicular cancer	0.000225	0.00033	CcSEcCtD
Paliperidone—Feeling abnormal—Epirubicin—testicular cancer	0.000224	0.000329	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—testicular cancer	0.000224	0.000329	CcSEcCtD
Paliperidone—Gastrointestinal pain—Epirubicin—testicular cancer	0.000223	0.000327	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—testicular cancer	0.000222	0.000325	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—testicular cancer	0.000219	0.000321	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—testicular cancer	0.000218	0.000319	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—testicular cancer	0.000217	0.000319	CcSEcCtD
Paliperidone—Urticaria—Epirubicin—testicular cancer	0.000216	0.000317	CcSEcCtD
Paliperidone—Pain—Doxorubicin—testicular cancer	0.000216	0.000316	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—testicular cancer	0.000216	0.000316	CcSEcCtD
Paliperidone—Body temperature increased—Epirubicin—testicular cancer	0.000215	0.000316	CcSEcCtD
Paliperidone—Abdominal pain—Epirubicin—testicular cancer	0.000215	0.000316	CcSEcCtD
Paliperidone—Hypersensitivity—Methotrexate—testicular cancer	0.000214	0.000315	CcSEcCtD
Paliperidone—Asthenia—Methotrexate—testicular cancer	0.000209	0.000306	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—testicular cancer	0.000208	0.000305	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000206	0.000302	CcSEcCtD
Paliperidone—Pruritus—Methotrexate—testicular cancer	0.000206	0.000302	CcSEcCtD
Paliperidone—Hypersensitivity—Epirubicin—testicular cancer	0.000201	0.000294	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—testicular cancer	0.0002	0.000294	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—testicular cancer	0.000199	0.000292	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—testicular cancer	0.000199	0.000292	CcSEcCtD
Paliperidone—Diarrhoea—Methotrexate—testicular cancer	0.000199	0.000292	CcSEcCtD
Paliperidone—Asthenia—Epirubicin—testicular cancer	0.000195	0.000287	CcSEcCtD
Paliperidone—Pruritus—Epirubicin—testicular cancer	0.000193	0.000283	CcSEcCtD
Paliperidone—Dizziness—Methotrexate—testicular cancer	0.000192	0.000282	CcSEcCtD
Paliperidone—Diarrhoea—Epirubicin—testicular cancer	0.000186	0.000273	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—testicular cancer	0.000186	0.000272	CcSEcCtD
Paliperidone—Vomiting—Methotrexate—testicular cancer	0.000185	0.000271	CcSEcCtD
Paliperidone—Rash—Methotrexate—testicular cancer	0.000184	0.000269	CcSEcCtD
Paliperidone—Dermatitis—Methotrexate—testicular cancer	0.000183	0.000269	CcSEcCtD
Paliperidone—Headache—Methotrexate—testicular cancer	0.000182	0.000268	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—testicular cancer	0.000181	0.000265	CcSEcCtD
Paliperidone—Dizziness—Epirubicin—testicular cancer	0.00018	0.000264	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—testicular cancer	0.000178	0.000262	CcSEcCtD
Paliperidone—Vomiting—Epirubicin—testicular cancer	0.000173	0.000254	CcSEcCtD
Paliperidone—Nausea—Methotrexate—testicular cancer	0.000173	0.000254	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—testicular cancer	0.000172	0.000253	CcSEcCtD
Paliperidone—Rash—Epirubicin—testicular cancer	0.000172	0.000252	CcSEcCtD
Paliperidone—Dermatitis—Epirubicin—testicular cancer	0.000172	0.000252	CcSEcCtD
Paliperidone—Headache—Epirubicin—testicular cancer	0.000171	0.00025	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—testicular cancer	0.000167	0.000245	CcSEcCtD
Paliperidone—Nausea—Epirubicin—testicular cancer	0.000162	0.000237	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—testicular cancer	0.00016	0.000235	CcSEcCtD
Paliperidone—Rash—Doxorubicin—testicular cancer	0.000159	0.000233	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—testicular cancer	0.000159	0.000233	CcSEcCtD
Paliperidone—Headache—Doxorubicin—testicular cancer	0.000158	0.000232	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—testicular cancer	0.00015	0.00022	CcSEcCtD
